Boston Scientific Co. (NYSE:BSX) EVP Wendy Carruthers Sells 6,983 Shares

Boston Scientific Co. (NYSE:BSXGet Free Report) EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $77.30, for a total value of $539,785.90. Following the completion of the sale, the executive vice president now owns 42,908 shares of the company’s stock, valued at approximately $3,316,788.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Wendy Carruthers also recently made the following trade(s):

  • On Monday, June 3rd, Wendy Carruthers sold 6,983 shares of Boston Scientific stock. The stock was sold at an average price of $75.33, for a total value of $526,029.39.

Boston Scientific Stock Down 0.6 %

Shares of NYSE:BSX opened at $76.11 on Friday. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $77.99. The firm has a market cap of $111.66 billion, a P/E ratio of 63.96, a P/E/G ratio of 2.63 and a beta of 0.78. The company has a quick ratio of 1.14, a current ratio of 1.66 and a debt-to-equity ratio of 0.47. The company’s 50-day moving average price is $75.23 and its two-hundred day moving average price is $68.02.

Boston Scientific (NYSE:BSXGet Free Report) last released its quarterly earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 EPS for the quarter, beating the consensus estimate of $0.51 by $0.05. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. The business had revenue of $3.86 billion for the quarter, compared to analysts’ expectations of $3.68 billion. As a group, research analysts forecast that Boston Scientific Co. will post 2.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Boston Scientific

Hedge funds and other institutional investors have recently made changes to their positions in the company. Louisiana State Employees Retirement System bought a new position in Boston Scientific in the fourth quarter valued at about $5,116,000. Glenmede Trust Co. NA grew its position in shares of Boston Scientific by 12.1% during the 3rd quarter. Glenmede Trust Co. NA now owns 10,442 shares of the medical equipment provider’s stock worth $551,000 after buying an additional 1,123 shares during the period. Sierra Summit Advisors LLC bought a new stake in shares of Boston Scientific during the fourth quarter worth approximately $8,038,000. TD Asset Management Inc raised its stake in shares of Boston Scientific by 10.7% during the fourth quarter. TD Asset Management Inc now owns 1,615,932 shares of the medical equipment provider’s stock worth $93,417,000 after buying an additional 155,565 shares during the last quarter. Finally, HealthInvest Partners AB acquired a new position in Boston Scientific in the fourth quarter valued at approximately $3,746,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BSX. UBS Group increased their price objective on shares of Boston Scientific from $74.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. JPMorgan Chase & Co. increased their price target on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. TD Cowen lifted their price objective on Boston Scientific from $65.00 to $77.00 and gave the company an “outperform” rating in a report on Thursday, March 7th. Needham & Company LLC reissued a “buy” rating and issued a $82.00 target price on shares of Boston Scientific in a report on Tuesday, June 18th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on Boston Scientific from $63.00 to $73.00 and gave the stock a “hold” rating in a research report on Thursday, April 25th. Three analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $77.41.

View Our Latest Stock Analysis on Boston Scientific

About Boston Scientific

(Get Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Further Reading

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.